| Balance sheet (USD) | FY 2025 ended Nov 30, 2025 | FY 2024 ended Nov 30, 2024 | FY 2023 ended Nov 30, 2023 | FY 2022 ended Nov 30, 2022 | FY 2021 ended Nov 30, 2021 | FY 2020 ended Nov 30, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 246.96M | 110.00M | 54.63M | 64.47M | 80.51M | 119.36M |
| Short-term investments | 244.67M | 215.21M | 161.79M | |||
| Receivables | 0 | 0 | 6.00M | |||
| Total current assets | 606.82M | 619.39M | 295.50M | 318.45M | 311.12M | 298.43M |
| Property, plant and equipment | 22.49M | 17.76M | 16.81M | 17.16M | 11.34M | 6.67M |
| Total assets | 688.13M | 669.34M | 355.60M | 416.76M | 476.77M | 396.34M |
| Accounts payable | 11.21M | 11.48M | 6.40M | 5.06M | 6.65M | 3.41M |
| Total current liabilities | 86.47M | 95.85M | 86.96M | 70.66M | 66.26M | 44.54M |
| Total liabilities | 149.39M | 142.35M | 155.10M | 113.06M | 134.47M | 106.07M |
| Retained earnings | -1.00B | -738.77M | -545.20M | -401.25M | -220.89M | -103.70M |
| Shareholders' equity | 538.75M | 526.99M | 200.49M | 303.70M | 342.30M | 290.27M |
From Nurix Therapeutics, Inc.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.